To assess the efficacy of adjuvant sclerotherapy after banding for the treatment of esophageal varices, a randomized trial was carried out of endoscopic variceal ligation (EVL) alone with sequential sclerotherapy versus sequential ligation-sclerotherapy (SLS) after banding with respect to variceal eradication, associated complications, and recurrence of varices. Methods: One hundred patients qualified for this study. Fourteen patients were not included for the following reasons: 6 chose not to participate, 4 had fundal varices, and 4 had some form of cancer. Of the remaining 86 patients in the study, 42 underwent EVL alone and the other 44 SLS. Variceal ligation was begun in the region of the gastroesophageal junction, with subsequent ligatures applied cephalad 3 to 5 cm; ligation was repeated every 2 weeks until variceal obliteration. For SLS, ligation was also begun in the region of the gastroesophageal junction and repeated until varices were reduced to F1 size. Subsequently, these patients underwent sclerotherapy with between 6 and 8 mL of sodium tetradecyl sulfate (free hand technique). Results: No significant differences were found between EVL alone and SLS with regard to variceal eradication, development of associated complications, and recurrent bleeding during a follow-up of 2 years. The probability of variceal recurrence requiring further treatment after 1 year was 14% for the SLS group and 26% for EVL group patients. Another year later, the probability of variceal recurrence was 24% and 45%, respectively, for the SLS and EVL groups. Conclusions: Because a significantly lower rate of variceal recurrence was found for SLS patients, sequential sclerotherapy followed by ligation to eradicate those varices too small to easily band may be a better procedure. (Gastrointest Endosc 2001;53:566-71.)
Endoscopic injection sclerotherapy for esophageal varices is undoubtedly beneficial in the management of active hemorrhage and the prevention of recurrent bleeding. [1] [2] [3] Nevertheless, it is associated with a substantial complication rate, and recurrent variceal bleeding is common before variceal obliteration is achieved. 4, 5 Endoscopic variceal ligation (EVL) is an alternative for the treatment of esophageal varices that is both efficacious and has fewer complications than sclerotherapy. [6] [7] [8] [9] However, EVL has several disadvantages. It does not produce sufficient injury to the muscularis propria to obliterate perforating venous channels. 10, 11 Thus it eradicates only superficial larger varices, whereas the eradication of smaller varices as well as the development of regions of fibrosis of the inner wall of the esophagus is not typically achieved. 12 The concept of combining EVL and sclerotherapy is appealing because it provides advantages common to both procedures. A prospective randomized trial was carried out of EVL alone compared with sequential ligationsclerotherapy (SLS) to assess variceal eradication, associated complications, and the recurrence of varices.
MATERIALS AND METHODS
From June 1995 to May 1997, all patients with cirrhosis, portal hypertension, and esophageal varices as revealed by endoscopy were included in this trial if they met the following criteria: no history or clinical evidence of hepatoma or other malignancy, no previous surgical or endoscopic treatment of esophageal varices, and no fundal varix. Patients qualifying for the study were randomly assigned to receive either EVL alone or SLS at the initial endoscopic examination according to a computer-generated randomization sequence. This study conformed to the guidelines of the Declaration of Helsinki and informed consent was obtained from all involved patients upon their entering the trial. Liver function reserve was classi-fied according to a modification of the Child-Pugh grading system. 13 An endoscopic assessment was made at each session according to standard criteria for findings of esophageal varices, as established by the Japanese Gastroenterological Endoscopy Society, 14, 15 in which the form of varices is graded as F0 (absence of esophageal varices), F1 (straight), F2 (winding), or F3 (nodule-beaded). All treatments were performed by endoscopists with mean experience of 7 years in caring for such patients.
For patients in the EVL group, variceal ligation was performed with either an endoscopic single-band ligating device with a plastic esophageal overtube (Top Co., Tokyo, Japan) or a multi-band ligator without using an overtube (Speedband, Boston Scientific Microvasive Co., Natick, Mass.). Ligation was begun in the region of the gastroesophageal junction with subsequent ligatures applied at a cephalad distance of 3 to 5 cm, and therapy was repeated to effect multiple ligations of individual channels at separate levels in the distal third of esophagus. Up to 4 or 5 bands were placed per endoscopic session, and the procedure was repeated every 2 weeks until variceal obliteration was achieved.
For patients in the SLS group, EVL was also begun in the region of the gastroesophageal junction and was repeated until varices were reduced to F1 size. Subsequently, patients underwent sclerotherapy to thrombose the main variceal channels and eradicate varices. Sclerotherapy was performed with sodium tetradecyl sulfate (free hand technique). 15 All visible small varices were injected. The total volume of sclerosant injected ranged from 6 to 8 mL, based on the number of varices. If extensive ulceration or stricture was noted during either course of therapy, the treatment was withheld, although endoscopic examination was continued every 2 weeks. For patients with less extensive ulceration, treatment was delivered to an area without ulceration. All patients received 1 g orally of granular sucralfate (Yuwan-S, Sawai, Osaka, Japan) as a mucosal protective agent, 4 times per day until eradication was achieved. After initial obliteration of varices, patients were followed as outpatients every 2 to 4 weeks for 2 years.
At each follow-up visit, data collected consisted of a short history, any signs of recurrent hemorrhage, and any changes in the clinical severity of the disease. Further endoscopy was performed at intervals of 3 months or for any episode of recurrent bleeding in order to detect the recurrence of any varices for patients from either group. Recurrent varices were treated with further ligation for patients from the EVL group and sclerotherapy for patients from the SLS group until clearance of varices from the gastroesophageal junction was again achieved. An esophageal stricture was diagnosed if a patient complained of dysphagia and there was endoscopic evidence of esophageal narrowing; dilatation was performed for esophageal strictures. All patients were evaluated at 2 years; study end points included death, loss to follow-up, treatment failure, and definitive surgical treatment for portal hypertension. Recurrent bleeding was defined as hemorrhage from recurrent varices or treatment-induced esophageal ulcer when active bleeding was seen or when stigmata of recent hemorrhage were present in the ulcer base. To eliminate the potential for bias, each examination was carefully reviewed and mapped by using either endoscopic photographs or videotape, and more than 2 experienced endoscopists assessed the results.
Some data are expressed as mean ± SD. For statistical testing, the chi-square test and Fisher exact test were used to compare categorical data. Continuous data were compared by Student's t test. The percentage of patients free of recurrent varices during the period after inclusion in the trial was calculated according to the Kaplan-Meier method, 16 and the log-rank test 17 was used to compare differences between groups. A p value of less than 0.05 was considered significant in statistical tests.
RESULTS
One hundred patients qualified for this study. Fourteen were not included because 6 chose not to participate, 4 had fundal varices, and 4 had some form of cancer. Of the remaining 86 patients, 42 were assigned to the EVL group and 44 to the SLS group. The 2 groups did not differ in terms of clinical features such as age, gender, etiology of cirrhosis, severity of liver disease, bleeding status, or variceal size (Table 1) . Active bleeding was found at the index endoscopy in 7 (17%) of the EVL group and 8 (18%) of the SLS group patients. In all of these 15 patients with active variceal bleeding, hemostasis was successfully achieved by variceal ligation within 12 hours. Three patients with bleeding from each group were treated with concomitant vasopressin infusion with same dosage for 2 days, and 1 patient from the EVL group required balloon compression to achieve hemostasis.
Eradication of varices was achieved for 36 EVL patients (86%) and for 40 SLS patients (91%) ( Table  2) , the mean number of sessions to eradication being, respectively, 3.5 ± 1.2 and 3.8 ± 1.4 (not significant). There were no significant differences in eradication according to variceal size and ChildPugh classification. There were no critical complications such as pulmonary embolism or esophageal perforation for any patient in either group (Table 3) although some patients did complain of fever, substernal pain, and dysphagia. All these complications, however, resolved spontaneously within 2 or 3 days and were not significantly different. Two patients from the EVL group and 3 from the SLS group developed bleeding ulcers that were successfully treated within 2 days after administration of a mucosal-protective agent treatment as mentioned above.
The rate of variceal recurrence was higher for patients in the ligation treatment group (Fig. 1) . One year after variceal eradication, the probability of variceal recurrence requiring further treatment was 26% for the EVL group and 14% for the SLS group. Another year later, the probability of variceal recurrence was 45% for EVL compared with 24% for SLS group patients, a significant difference. Throughout the entire treatment and follow-up period, recurrent bleeding from all sources occurred in 8 EVL group patients and 10 SLS group patients (Table 4 ). In 6 cases (2 EVL and 4 SLS) a treatmentinduced esophageal ulcer was the source of further bleeding. Three patients in each group developed portal hypertensive gastropathy, and for 3 cases in each group recurrent varices were the source of recurrent bleeding. Seventy percent of recurrent variceal bleeding occurred within the first 6 months of follow-up. No significant difference in recurrent bleeding was found between the 2 groups in this study. Twenty-five patients (13 EVL, 12 SLS) died during follow-up. There was no difference detected between the 2 groups with respect to mean mortality rates (Table 5 , power = 83%). Two patients in the EVL group died from recurrent bleeding and 10 from hepatic decompensation, which included 3 patients who developed hepatocellular carcinoma. In the SLS group, 1 patient died from recurrent bleeding and 9 from hepatic failure, including 4 from hepatocellular carcinoma. Of the remaining, 3 patients died from other systemic diseases (1 EVL patient due to diabetic coma and 2 SLS patients of cardiac diseases). The mortality rate was related to Child-Pugh grade at admission, with significantly fewer deaths occurring among patients with ChildPugh grade A compared with grade B and C categories (Table 5 ). Hepatic failure and later developing hepatocellular carcinoma in both groups were associated with higher mortality. There was no relationship between endoscopic treatment and mortality.
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DISCUSSION
Endoscopic techniques have been used to treat esophageal variceal hemorrhage for over 50 years 18 and are now accepted as the first-line treatment for this type of bleeding. 19, 20 Sclerotherapy has been widely accepted as the treatment of choice for treating bleeding esophageal varices. 1-3 Randomized, controlled studies have shown sclerotherapy to be superior to medical treatment for the control of actively bleeding varices and the long-term prevention of recurrent bleeding. 1, 20, 21 Nevertheless, the results of sclerotherapy have not been ideal, the procedure having been associated with a host of complications, of which some have resulted in substantial morbidity and mortality. 22, 23 Thus, the shortcomings of sclerotherapy have fostered the development of new modalities of treatment for esophageal varices such as EVL. 24 Endoscopic variceal ligation is based on the widely used technique of band ligation of hemorrhoids. The mucosa and submucosa of the esophagus containing the variceal channels are ensnared, leading to strangulation, sloughing, and eventual fibrosis, ideally with obliteration of the varices. A meta-analysis of randomized clinical trials 9 revealed that EVL is a well-established technique for the treatment of esophageal varices with the potential for more rapid variceal obliteration, fewer treatment-related complications, and possibly less recurrent bleeding and a reduction in mortality as compared with sclerotherapy.Although EVL may achieve results that are at least as good as sclerotherapy with fewer complications and lower mortality, 6-9 sclerotherapy cannot simply be replaced with EVL because of several technical drawbacks associated with EVL. During EVL the field of vision is reduced somewhat because of the cylinder attachment at the end of the endoscope. The cylinder also impedes the selective aspiration of blood or secretion because the area of suction is essentially equal to the cylinder circumference. In addition, some varices may be better suited for treatment by sclerotherapy; for instance, previously treated small varices embedded in a nonpliable section of mucosa that are thus difficult to aspirate into the cylinder attachment. Such varices cannot be adequately and effectively treated with EVL. 12 The concept of combining EVL and sclerotherapy is appealing because it combines the advantages of both procedures while avoiding inadequacies or limitations associated with either technique.
There are several studies of the combination therapy. 12, [25] [26] [27] [28] [29] In the controlled trial of Hashizume et al., 12 patients with bleeding esophageal varices were randomized to either EVL or sclerotherapy at the first therapy session followed by sclerotherapy for all subsequent sessions. The design of this trial differs from ours in that combined therapy was compared with sclerotherapy rather than EVL. Nevertheless, these investigators found that patients undergoing combined therapy required a lower total volume of sclerosant and had a lower rate of fever, pain, pleural effusion, and early ulcer in comparison with patients undergoing sclerotherapy alone. Complications were more frequent for patients undergoing sclerotherapy compared with banding as noted in previous studies. 6, 8, 30, 31 The most serious complication was a sclerotherapy-related esophageal perforation that led to the death of a patient. 32 In our sequential therapy regimen, it is our belief that the complication rate did not increase subsequent to sclerotherapy because only a small amount of sclerosant was injected to eradicate small F1 varices. The study by Laine et al. 25 found that combined ligation plus sclerotherapy increased the number of treatment sessions and the time required for variceal obliteration as compared with ligation alone. But in the same study, the numerical differences in complications between those two groups were too small to be statistically significant. This might be the reason that these investigators concluded that combined therapy offers no benefit over ligation alone. Saeed et al., 26 on the other hand, found no difference in number of treatment sessions but did not report on the time required to achieve obliteration. They also found that patients receiving combined therapy had a significantly higher rate of deep ulcers and dysphagia. However, the studies of Laine et al. 25 and Saeed et al. 26 had different designs than ours. They used combined therapy by ligating each variceal column distally followed by injection of sclerosant proximal to the ligation site.
Bhargava and Pokharna 27 used methodology similar to ours and found that patients undergoing combined therapy had more complete obliteration without a significant increase in complications. However, the patients undergoing combined therapy needed significantly more endoscopic sessions than those who underwent EVL alone. This study did not assess the time required to achieve eradication or the long-term recurrence rate. In our study, SLS alone achieved variceal eradication for a similar proportion of patients as compared with EVL. The duration of the eradication process also appeared not to differ significantly in terms of the number of sessions (3.5 ± 1.2 vs. 3.8 ± 1.4) because the procedure for both groups was essentially the same up to the point that the varices were reduced to an F1 classification. Based on the results of our study, sequential sclerotherapy after banding may produce results superior to those obtainable with either treatment alone. The SLS technique has the same advantage of rapid eradication as banding and fewer complications associated with subsequent sclerotherapy than are encountered in patients initially treated with sclerotherapy alone.
The variceal recurrence rate 2 years after therapy was significantly lower for patients who underwent SLS compared with those who had EVL alone in our study. According to Stiegmann and Goff, 33 varices may be eradicated with repeated ligation, but recanalization subsequently occurs around the treated areas, and/or some variceal channels are likely to be missed. Endoscopic variceal ligation is typically more successful at eradicating larger rather than smaller varices, whereas eradication of smaller varices, as well as fibrosis of the inner wall of the esophagus, may not be achieved with EVL. 12 Microscopic examination of ligation sites in animal models and human postmortem studies has revealed that the penetration of inflammation and scarring is typically confined to the submucosal layer of the esophageal wall 34, 35 and did not produce sufficient injury to the muscularis propria to obliterate perforating venous channels. By contrast, sclerosant can induce fibrosis and thickening of the inner wall of esophagus, 10,36 which appears to achieve a more thorough eradication of esophageal varices and also appears to prevent recurrence compared with ligation therapy. In the prospective, randomized trial of Lo et al. 28 the addition of low-dose sclerotherapy after repeated banding proved safe and effective in the prevention of recurrence of esophageal varices and recurrent bleeding. However, there was no difference in recurrent variceal bleeding after eradication in our study for both treatment groups because any recurrent varices were identified and treated early as a result of endoscopic surveillance at 3-month intervals during follow-up.
Mortality rates were similar for both groups in our study, the absence of any apparent relationship between endoscopic treatment and mortality in this trial being at variance with other studies. [6] [7] [8] [9] In our study, most patients died of hepatic failure and hepatocellular carcinoma in both groups and death was clearly associated with liver function reserve (Table 5 ). Similar results have been reported by other investigators, 13, 30, 31 suggesting that good liver function is more important in determining survival than any form of endoscopic treatment alone. The SLS, in conclusion, has the same advantage of rapid eradication as ligation, but without the increase in complications associated with subsequent sclerotherapy. Adjuvant sclerotherapy after ligation achieved a more thorough eradication of esophageal varices and prevented their recurrence as compared with ligation alone. It is our belief that it is the best method for endoscopic variceal treatment.
